JPH01313433A - Anti-hiv agent - Google Patents
Anti-hiv agentInfo
- Publication number
- JPH01313433A JPH01313433A JP14544088A JP14544088A JPH01313433A JP H01313433 A JPH01313433 A JP H01313433A JP 14544088 A JP14544088 A JP 14544088A JP 14544088 A JP14544088 A JP 14544088A JP H01313433 A JPH01313433 A JP H01313433A
- Authority
- JP
- Japan
- Prior art keywords
- hiv
- agent
- fucoidan
- active ingredient
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 title claims abstract description 9
- 229940124411 anti-hiv antiviral agent Drugs 0.000 title claims abstract description 9
- 229920000855 Fucoidan Polymers 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 10
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 208000030507 AIDS Diseases 0.000 abstract description 6
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 208000011580 syndromic disease Diseases 0.000 abstract description 4
- 241000700605 Viruses Species 0.000 abstract description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 abstract description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 abstract description 2
- 241000227647 Fucus vesiculosus Species 0.000 abstract description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 abstract description 2
- 238000007911 parenteral administration Methods 0.000 abstract description 2
- 230000002265 prevention Effects 0.000 abstract description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract 2
- 206010061598 Immunodeficiency Diseases 0.000 abstract 1
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 1
- 241000199919 Phaeophyceae Species 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000007813 immunodeficiency Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
- 241000894007 species Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
【発明の詳細な説明】
〔産業上の利用分野〕
本発明は、ヒト免疫不全症ウィルス（以下１”’ ＨＩ
Ｖ Ｊと略称する）に関し、更に詳細には、特定の糖脂
質を有効成分とする新しい抗ｆ（ＩＶ剤に関する。[Detailed Description of the Invention] [Industrial Application Field] The present invention relates to human immunodeficiency virus (hereinafter referred to as 1"' HI
In particular, the present invention relates to a new anti-f (IV agent) containing a specific glycolipid as an active ingredient.
後天性免疫不全症候群（Ａｃｑｕｉｒｅｄ Ｉｍｍｕｎ
ｅＤｅｆｉｃｉｅｎｃｙ Ｓｙｎｄｒｏｍ ； Ａ１１
）Ｓ〕は、 ）Ｉｆｆ［Ｈｕｍａｎ Ｉｍｙｎｕｎｏｄ
ｅｆｉｃｉｅｎｃｙ Ｖｉｒｕｓ ； Ｎａｔｕｒｅ。Acquired Immune Deficiency Syndrome
eDeficiency Syndrome; A11
)S] is )Iff[Human Imynunod
efficiency Virus; Nature.
き起される重篤な５Ｐ！、役不全症でアリ、その死亡率
が非常に高いことから、かかるＨＩＶ感染及びＡＩ Ｄ
Ｓに対する対策は大きな社会的課題とさえなっている。A serious 5P awakening! , HIV infection and AIDs, as the mortality rate is very high.
Countermeasures against S have even become a major social issue.
現在臨床的に効果があると認められている抗Ｉ（ＩＶ剤
としては、逆転写酵素の阻害作用を有するアシドチミジ
ン（ＡＺＴ ）が知られているが、その臨床的効果は、
尚不十分で６Ｊ）、更にこれによる副作用、例えば骨髄
（造血組織）の障害や頭痛、けいれん等の神経症状等の
副作用が強いという問題を抱えている。殊にＨＩＶは、
その遺伝子がプロウィルスとなって感染した細胞の染色
体に潜シ込み遺伝病のような状態になっていることから
必然的に薬剤の長期投与が要求されておｆｉ、ＡＺＴの
有するかかる’ｒａｒｅ用は、これを抗ＨＩＶ剤として
用いる場合の大きな障害となっている。Acidothymidine (AZT), which has an inhibitory effect on reverse transcriptase, is known as an anti-I (IV drug) that is currently recognized to be clinically effective.
However, it is still insufficient (6J), and there is a further problem in that it causes strong side effects such as damage to the bone marrow (hematopoietic tissue) and neurological symptoms such as headaches and convulsions. In particular, HIV
Since the gene becomes a provirus and infiltrates the chromosomes of infected cells, causing a condition similar to a genetic disease, long-term administration of the drug is inevitably required. This is a major obstacle in using it as an anti-HIV agent.
また、）ＩＩＶ感染者が、ＡＩＤＳを発症するまでには
、通常極めて長い臨床的潜伏期がありその為、感染予防
対策をたてることが非常に困難とされている。Furthermore, there is usually an extremely long clinical incubation period before a person infected with )IIV develops AIDS, which makes it extremely difficult to take measures to prevent infection.
かかる現状からＭＩＶ感染及びＡＩ ＤＳに対して奏効
する新しい医薬製剤の開発が斯界で待ち望まれている。Under these circumstances, the development of new pharmaceutical preparations that are effective against MIV infection and AIDS is eagerly awaited.
本発明者は、１（ＩＶに対して作用を有する化合物につ
いて鋭意研究金おこなった結果、フコイダンが抗１−Ｉ
ＩＶ剤として有効であることを見出し、本発明全完成し
た。As a result of intensive research into compounds that have an effect on 1-IV, the present inventor discovered that fucoidan has an anti-1-I effect.
It was found to be effective as an IV agent, and the present invention was completed.
すなわち本発明は、フコイダンを有効成分として含有す
る抗１（ＩＶ剤を提供するものである。That is, the present invention provides an IV agent containing fucoidan as an active ingredient.
本発明の有効成分であるフコイダン
（Ｆｕｃｏｉｄａｎ又はＦｕｃｏｉｄｉｎ ）は、褐４
類の一種であるフッカ ベシクロサス（ＦｕｃｕｓＶｅ
ｓｉｃｕｌｏａｕｓ ）から抽出され、分子内に鉱酸を
含有するフコースを多く宮む？リサツヵライドであり、
現在、Ｌ−７コースの原料として主に用いられているも
のである。Fucoidan or Fucoidin, which is the active ingredient of the present invention, is brown 4
Fucus Vesiculosus
siculoas) and contains a lot of fucose, which contains mineral acids in the molecule? It is Risatsuka Ride,
Currently, it is mainly used as a raw material for L-7 course.
フコイダンはすでに市販されている安全性の高い化合物
であり（例えばシグマカタログ番号１” ５６３１ ）
、本発明においてはこの市販品を用いることができる
。Fucoidan is a highly safe compound that is already commercially available (e.g. Sigma catalog number 1” 5631).
This commercially available product can be used in the present invention.
本発明の抗ｆ（ＩＶ剤は、上記フコイダンを必、須成分
とし、通常その薬理有効量と共に適当な医薬＃！剤担体
を配合することにより調製され゛る。The anti-f(IV) agent of the present invention contains the above-mentioned fucoidan as an essential ingredient, and is usually prepared by blending a pharmacologically effective amount thereof with a suitable pharmaceutical agent carrier.
製剤担体としては、使用形態に応じた製剤をｇＩｌ製す
るのに通常慣用される元項剤、増量剤、保湿剤、崩壊剤
、表面活性剤等の賦形剤ないし希釈剤等のいずれもが使
用できる。製剤組成物の形態はこれが上記有効成分を効
果的に含有する状態であれば籍に限定はなく、例えば、
錠剤、粉剤、顆粒剤、丸剤等の固剤や通常液剤、懸濁剤
、乳剤等の液剤であることができる。またこれを使用前
に適当な担体の添加によって液状となし得る乾燥品とす
ることもできる。上記製剤組成物には、必要に応じて通
常の各種添加剤、例えば溶解補助剤、緩衝剤、無痛化剤
、保存剤、着色剤等を添加することもでき、更に他の医
薬品を組み合せ配合することもできる。As a pharmaceutical carrier, any of excipients or diluents such as excipients, bulking agents, humectants, disintegrants, surfactants, etc., which are commonly used to prepare pharmaceutical preparations according to the usage form, can be used. Can be used. The form of the pharmaceutical composition is not limited as long as it effectively contains the above-mentioned active ingredient; for example,
They can be solid preparations such as tablets, powders, granules, and pills, and liquid preparations such as liquid preparations, suspensions, and emulsions. It can also be made into a dry product that can be made into a liquid by adding a suitable carrier before use. Various conventional additives such as solubilizing agents, buffering agents, soothing agents, preservatives, coloring agents, etc. may be added to the above pharmaceutical composition as necessary, and other pharmaceuticals may also be combined. You can also do that.
本発明の抗１（ＩＶ剤は、該製剤組成物の形態に応じた
適当な投与経路で投与される。投与方法も特に限定はな
く、内用、外用及び注射によることができる。注射剤は
、例えば静脈内、筋肉内、皮下、皮内、腹腔内等に投与
し得、外用剤には、全開等も包含される。The anti-1 (IV agent) of the present invention is administered by an appropriate administration route depending on the form of the pharmaceutical composition.The administration method is also not particularly limited, and can be administered internally, externally, or by injection. For example, it can be administered intravenously, intramuscularly, subcutaneously, intradermally, intraperitoneally, etc., and external preparations also include fully administered.
本発明抗ＨＩＶ剤の投与量は、その製剤形態、投与方法
、使用目的及びこれを通用される患者の年齢、体重、病
状等に応じて適宜設定され、一定ではないが一般には製
剤中に含有される有効成分の量が一成人当シ、経口投与
の場合０．１２〜１０１程度、非経口投与の場合０．１
２〜１２程度とすることが好ましく、製剤中の有効成分
量は、この投与量に従って適宜設定される。なお、投与
は必要に応じて１日数回に分けて行うことも可能である
。The dosage of the anti-HIV agent of the present invention is determined appropriately depending on its formulation form, administration method, purpose of use, and the age, weight, medical condition, etc. of the patient to whom it is administered, and although it is not fixed, it is generally contained in the formulation. The amount of active ingredient administered per person is approximately 0.12 to 101 for oral administration, and 0.1 for parenteral administration.
It is preferable to set it as about 2-12, and the amount of active ingredients in a formulation is suitably set according to this dosage. Note that the administration can be divided into several times a day if necessary.
本発明の抗ＨＩＶ剤は、 ）ＩＩＶ感染の予防及びＡＩ
ＤＳ並びにその関連症候群圧の発症予防韮びに治療に
有効でめ９、またその有効成分であるフコイダンの細胞
毒性が低いことから、長期の投与にも好適に使用し得る
ものである。The anti-HIV agent of the present invention has the following features: ) Prevention of IIV infection and AI
It is effective in preventing and treating the onset of DS and related syndrome pressure9, and its active ingredient, fucoidan, has low cytotoxicity, so it can be suitably used for long-term administration.
従って、本発明の抗１（ＩＶ剤は健常人のかかるＨＩＶ
感架の予防、無症候感染者（キャリア）の発症予防なら
びに治療及び発症したＡＩＤＳならびに戚患者の治療に
極めて有用である。Therefore, the anti-1 (IV agent) of the present invention is effective against such HIV in healthy people.
It is extremely useful for preventing infection, preventing and treating asymptomatic carriers, and treating AIDS patients and their relatives who have developed AIDS.
以下、本発明抗ＨＩＶ剤及びその効果をよシー層間らか
にするため、実施例を挙けて更に本発明を説明するが、
本発明はこれら実施例に限定されるものではない。なお
以下実施例におけるフコイダンは、シグヤ社のもの（カ
タログ番号Ｆ５６３１）を用いた。Hereinafter, the present invention will be further explained with reference to examples in order to clearly demonstrate the anti-HIV agent of the present invention and its effects.
The present invention is not limited to these examples. Note that the fucoidan used in the following examples was manufactured by Shiguya Co., Ltd. (catalog number F5631).
実施例ル
シチンーコレステロールーフコイダンからなるす？ソー
ム分散液（フコイダン懸濁ｇ）を調製した〔保田立二９
等、免疫実験操作法ｉｘ 、ｐ ２９８９−２９９４
（１９８０）Ｊ。即ち、５ｍＭ卵黄レシチン、１０ｍＭ
コレステロール、１ ｌｎＭホスファチシン酸及び１〜
ｔｏｏａｙ／−７ｊイダンを有機溶媒（クロロホルム：
メタノール＝２ ： １１ Ｖ／Ｖ）中に容積比が順次
２：１：１：１となるように混合した。有機溶媒を留去
後、緩衝液（リン酸緩衝生理食塩液−ＰＢＳ ）を加え
、ミキサー（Ｖｏｒｔｅｘ ｍ１ｘｅｒ ）で攪拌して
、ｌ−中にフコイダンを１■含有する分散ｇ剤を調製し
た。Example: Consisting of lucitin-cholesterol-fucoidan? A soma dispersion (fucoidan suspension g) was prepared [Tatsuji Yasuda 9
et al., Immunology Experimental Procedures ix, p. 2989-2994.
(1980)J. i.e. 5mM egg yolk lecithin, 10mM
Cholesterol, 1 lnM phosphatic acid and 1 to
tooay/-7j idan in an organic solvent (chloroform:
The mixture was sequentially mixed in methanol (2:11 V/V) at a volume ratio of 2:1:1:1. After distilling off the organic solvent, a buffer solution (phosphate buffered saline-PBS) was added and stirred with a mixer (Vortex m1xer) to prepare a dispersion g agent containing 1 part of fucoidan in 1 volume.
実施例２ 薬理試験： （１）抗ＨＩＶ活性 抗）ＩＩＶ活性を下記の方法により試験した。Example 2 Pharmacological test: (1) Anti-HIV activity Anti)IIV activity was tested by the following method.
即ちｓ ５ Ｘ １０３ｐｆｕ／ｆｆ１７！のｆｉＩ
Ｖ ５０ ｔｔｌと種々濃度のフコイダン懸濁液（ＰＢ
Ｓ ） ２００μｇとを混合して、３７℃下に３０分間
インキュベートした。このウィルス混合ｇ２５０μＥを
ｓ ２ Ｘ １０’ Ｃｅ１ｌｓ／ｄ培地（ＲＰＭＩ
−１６４０＋１０％ＦＣＳ ）に調製したＭＴ −４細
胞（ｍ１ｙｏｓｈｉ 、 １．等、 Ｇａｎｎ Ｍｏｎ
ｏｇｒ、、 ２８ 。That is, s 5 X 103 pfu/ff17! fiI of
V 50 ttl and various concentrations of fucoidan suspension (PB
S) was mixed with 200 μg and incubated at 37° C. for 30 minutes. 250 μE of this virus mixture was added to s 2 × 10' Ce1ls/d medium (RPMI
-1640+10%FCS) prepared into MT-4 cells (Mlyoshi, 1. et al., Gann Mon.
ogr,, 28.
ｐ２１９−２２８（１９８２）］の０．２５−に加えて
４日間培養後、ウィルスの感染状況を間接螢光抗体法（
Ｈａｒａｄａ Ｓ、等、 ５ｃｉｅｎｃｅ 。p219-228 (1982)], and after culturing for 4 days, the virus infection status was determined by indirect fluorescent antibody method (
Harada S, et al. 5science.
２２９ 、ｐ５６３−５６６ （１９８５）；Ｔａｋｅ
ｕｃｈｉ、 Ｙ１等Ｊｐｎ、 Ｊ、 Ｃａｎｃｅｒ Ｒ
ｅｓ、 （Ｇａｎｎ） 。229, p563-566 (1985); Take
uchi, Y1 etc. Jpn, J, Cancer R
es, (Gann).
７８、ｐＨ−１５（１９８７） 〕によシ調ぺた。ウ
ィルス感染細胞（）ＩＩＶ抗原陽性細胞）の６分率←）
を算出した結果を下記第１表に示す。78, pH-15 (1987)] Yoshicho Peta. 6% of virus-infected cells () IIV antigen-positive cells ←)
The results of the calculation are shown in Table 1 below.
第１表
上記結果よシ、本発明抗ＨＩＶ剤は、有効にＨＩＶウィ
ルス感染を防止することがわかる。The above results in Table 1 show that the anti-HIV agent of the present invention effectively prevents HIV virus infection.
（２） 細胞毒性 フコイダンの細胞毒性を上記（１）に準じて試験した。(2) Cytotoxicity The cytotoxicity of fucoidan was tested according to (1) above.
即ち、ｌＸｌ０’細胞／−に調製したＭＴ−４，ｌｆｉ
胞を種々濃度のフコイダンの存在下に、４日間培養後そ
の細胞数をカウントし、細胞毒性を評価した。結果を下
記第２表に示す。That is, MT-4, lfi prepared in lXl0' cells/-
The cells were cultured for 4 days in the presence of various concentrations of fucoidan, and the number of cells was counted to evaluate cytotoxicity. The results are shown in Table 2 below.
＠２表
上記結果よシ、フコイダンには著名な細胞毒性がないこ
とが明らかである。From the above results in Table 2, it is clear that fucoidan has no significant cytotoxicity.
以上 出願人 株式会社日本抗体研死所 代理人 弁理士 有 賀 三 幸that's all Applicant: Japan Antibody Research Institute, Inc. Agent: Patent attorney Miyuki Yuga
Claims (1)
する抗ＨＩＶ剤。1. An anti-HIV agent characterized by containing fucoidan as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14544088A JPH01313433A (en) | 1988-06-13 | 1988-06-13 | Anti-hiv agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14544088A JPH01313433A (en) | 1988-06-13 | 1988-06-13 | Anti-hiv agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH01313433A true JPH01313433A (en) | 1989-12-18 |
Family
ID=15385290
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14544088A Pending JPH01313433A (en) | 1988-06-13 | 1988-06-13 | Anti-hiv agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH01313433A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009181A1 (en) * | 1989-02-10 | 1990-08-23 | Taiho Pharmaceutical Co., Ltd. | Anti-hiv drug |
| WO1997047208A1 (en) * | 1996-06-12 | 1997-12-18 | Takara Shuzo Co., Ltd. | Foods or drinks |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| WO2010086746A2 (en) | 2009-01-28 | 2010-08-05 | Life Science Nutrition As | Compositions and methods of treating viral infections |
| WO2019074387A2 (en) | 2017-10-12 | 2019-04-18 | Bojan Pavlovic | F-fucoidan, desulfated f-fucoidan, and its processed derivatives in terms of desulfated oligo-fucose as inhibitors of gastrointestinal infection |
-
1988
- 1988-06-13 JP JP14544088A patent/JPH01313433A/en active Pending
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990009181A1 (en) * | 1989-02-10 | 1990-08-23 | Taiho Pharmaceutical Co., Ltd. | Anti-hiv drug |
| WO1997047208A1 (en) * | 1996-06-12 | 1997-12-18 | Takara Shuzo Co., Ltd. | Foods or drinks |
| US6812220B2 (en) | 2001-08-29 | 2004-11-02 | University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| US7163930B2 (en) | 2001-08-29 | 2007-01-16 | The University Of British Columbia | Pharmaceutical compositions and methods relating to fucans |
| WO2010086746A2 (en) | 2009-01-28 | 2010-08-05 | Life Science Nutrition As | Compositions and methods of treating viral infections |
| US8697670B2 (en) | 2009-01-28 | 2014-04-15 | Life Science Nutrition As | Compositions and methods of treating viral infections |
| US9789142B2 (en) | 2009-01-28 | 2017-10-17 | Life Science Nutrition As | Method of increasing lean body mass |
| WO2019074387A2 (en) | 2017-10-12 | 2019-04-18 | Bojan Pavlovic | F-fucoidan, desulfated f-fucoidan, and its processed derivatives in terms of desulfated oligo-fucose as inhibitors of gastrointestinal infection |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20090142427A1 (en) | Composition and its Therapeutic Use | |
| AU2007203159B2 (en) | Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone | |
| JPH06505231A (en) | Use of quinones in the treatment of cancer or AIDS | |
| KR960000432B1 (en) | Pharmaceutical composition | |
| AU662883B2 (en) | Use of trinitrobenzenes or carminic acid in the treatment of cancer or viral diseases | |
| DE60032915T2 (en) | GALLIUM COMPLEXES OF 3-HYDROXY-4-PYRONES FOR THE TREATMENT OF INFECTIONS CAUSED BY INTRA-CELLULAR PROCYNOTES, DNA AND RETRO VIRUSES | |
| JPH01313433A (en) | Anti-hiv agent | |
| PL185678B1 (en) | Novel applications of lysozime dimers | |
| JPH05504774A (en) | Use of metalloporphyrins to enhance AIDS treatment | |
| JP3631245B2 (en) | Use of hymenoptera venom for the manufacture of a medicament for the treatment of DNA virus infection | |
| KR100302994B1 (en) | New application as a medicament for multipotent Parapox immunogenic factors from attenuated non-immunogenic Foxvirus or Parapoxvirus | |
| EP2722053B1 (en) | Antibacterial agent for treating infectious diseases of bacterial origin | |
| US5059592A (en) | Composition for prevention and (or) treatment of AIDS | |
| JP2589120B2 (en) | Anti-HIV agent | |
| JPH02191225A (en) | Antiviral agent | |
| JP2848634B2 (en) | Drugs with immunosuppressive action | |
| AU2003234637B2 (en) | Methods and compositions for inhibiting HIV replication | |
| CH694687A5 (en) | Drugs to treat viral infections from Vernonia Oligocephalus. | |
| US5229368A (en) | Composition for prevention and (or) treatment of Aids | |
| WO1991016916A1 (en) | Antineoplastic agent | |
| Osváth et al. | Herpes Encephalitis | |
| HRP920891A2 (en) | Quinone preparation | |
| JPH01172321A (en) | Antiviral agent containing 6-0-substituted-d-gluco-delta-lactam | |
| JP2013018729A (en) | Potency enhancing oral preparation for therapeutic agent for alzheimer disease | |
| WO1997000685A1 (en) | Use of substituted pentose or hexose derivates in the treatment of aids and aids related neoplastic disorders |